Michihisa Nishiyama

Michihisa Nishiyama led the global development of tacrolimus (Prograf®), a standard immunosuppressant, to a successful conclusion at Fujisawa Pharmaceutical Co. Ltd. (currently Astellas Pharma Inc.) After launching tacrolimus, he created a marketing network across more than 70 countries, including the US and European countries.

He has experience in both global development/marketing and managing biotech ventures.

He became an outside director of Healios in 2014, then a director in charge of domestic development since 2016.